- Previous Close
45.20 - Open
46.70 - Bid 44.59 x --
- Ask 44.64 x --
- Day's Range
44.56 - 45.45 - 52 Week Range
33.00 - 56.89 - Volume
2,889,318 - Avg. Volume
5,147,353 - Market Cap (intraday)
18.562B - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
-- - EPS (TTM)
-0.25 - Earnings Date --
- Forward Dividend & Yield 0.10 (0.22%)
- Ex-Dividend Date Jul 4, 2024
- 1y Target Est
--
BGI Genomics Co., Ltd. provides sequencing services and a portfolio of genetic tests for medical institutions, research institutions, and other public and private partners in China and internationally. The company offers DNA, RNA, and customized sequencing services; and non-invasive prenatal testing, reproductive health screening, newborn genetic screening, and clinical exome sequencing services, as well as clinical and research solutions for oncology. It also offers laboratory solutions for the detection and diagnosis of patients suspected with COVID-19; SARS-CoV-2 IgM and IgG antibody detection kit; and real-time fluorescent RT-PCR kit for detecting SARS-CoV-2. The company offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. BGI Genomics Co., Ltd. was founded in 1999 and is headquartered in Shenzhen, China.
www.bgi.com3,752
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 300676.SZ
View MorePerformance Overview: 300676.SZ
Trailing total returns as of 11/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300676.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300676.SZ
View MoreValuation Measures
Market Cap
18.56B
Enterprise Value
14.68B
Trailing P/E
236.18
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.52
Price/Book (mrq)
1.89
Enterprise Value/Revenue
3.64
Enterprise Value/EBITDA
16.75
Financial Highlights
Profitability and Income Statement
Profit Margin
-2.52%
Return on Assets (ttm)
-0.64%
Return on Equity (ttm)
-1.00%
Revenue (ttm)
4.03B
Net Income Avi to Common (ttm)
-101.62M
Diluted EPS (ttm)
-0.25
Balance Sheet and Cash Flow
Total Cash (mrq)
4.71B
Total Debt/Equity (mrq)
4.02%
Levered Free Cash Flow (ttm)
-707.47M